Review Article OPEN ACCESS | Freely available online
Page 1 of 7
Volume 2 | Issue 2 | e1000015 Chee Kong Yap
Antiviral compounds from marine bivalves for evaluation against
SARS-CoV-2
Chee Kong Yap*
Department of Biology, Faculty of Science, Universiti Putra Malaysia,43400 UPM, Serdang, Selangor, Malaysia.
Abstract: A novel corona virus (SARS-CoV-2) outbreak is claiming thousands of lives worldwide. As of April 10, 2020, the number of laboratory-confirmed cases of SARS-CoV-2 infected has reached over 1.7 million (1,725,126) with over 0.1 million (104,878) recorded deaths. This pandemic has ushered an urgent need for identifying drugs which can inhibit the survival of SARS-CoV-2. On one hand,
researchers from across globe are searching for various sources of potential antiviral compounds. On the other hand, high diversity, ecological adaptation, defensive system against wide range of viruses makes marine bivalves as a great source of antiviral compounds. Ocean environment has provided a rich diversity of compounds from structural classes including alkaloids, terpenoids, steroids, polysaccharides, and peptides etc., many of which have shown potential activities against bacterial, fungal, parasitic and viral diseases. In this scenario, potential antiviral compounds from marine bivalves, worth evaluating against SARS-CoV-2 have been briefly summarized in this present review. Keywords: Antiviral compounds; marine bivalves; antiviral potency; SARS-CoV-2; novel corona virus.
Citation: Chee Kong Yap (2020) Antiviral compounds from marine bivalves for evaluation against SARS-CoV-2, Journal of PeerScientist
2(2): e1000015. Received: April 01, 2020; Accepted: April 21, 2020; Published: April 22, 2020. Copyright: © 2020 Chee Kong Yap. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Competing Interests: The author have declared that no competing interests exist. * E-mail: [email protected] | Phone: + 603-9769 6616.
I. INTRODUCTION
novel corona virus (nCoV) outbreak in late 2019 at
Wuhan, China is claiming thousands of lives across globe leaving humans in a predicament situation of
novel corona virus disease (COVID-19) pandemic [1]. As
of April 10, 2020, the number of laboratory-confirmed
cases of SARS-CoV-2 infected has reached over 1.7 million (1,725,126) with over 0.1 million (104,878)
recorded deaths [2]. The incremental numbers for both
total cases and total deaths signifies that the coronavirus is infecting humans exponentially. Present identified novel
corona virus belongs to same family of recent Severe
Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks [3-4]. Zhang et
al. 2002 showed that the outbreaks of the Severe Acute
Respiratory Syndrome (SARS) in many regions of Asia
were well described by the logistic model, and the control measures implemented by governments are effective [5].
Christian et al. 2014 reported that the number of patients
diagnosed positive with Middle East Respiratory Syndrome (MERS) are with known travel history between
cities in King Fahd Hospital and all other hospitals,
between March 26 until April 28, 2014 [6]. The above two
studies shows the peak of coronavirus COVID-19 shall be
reaching a plateau and this level-off pattern would
indicate the fall of the pandemic overall cases. Presumably, any viral outbreak will eventually become
less contagious and harmful, and less of the public health
concern. Only the discovery or repurposing of potential antiviral drugs (ADs) can be a good answer if not the best
to cure and save the infected patients’ lives at present, and
to control this viral pandemic COVID-19 spread.
Oceans hold exclusive supplies that can offer a wide
spectrum of natural products, principally from
invertebrates such as bivalves. As infectious diseases change and grow endurance to existing pharmaceuticals,
the marine environment can provide an innovative
protection against bacterial and viral diseases [7].
Limitations in antiviral treatments and the occurrence of novel pathogenic viruses have added to a mounting
requirement for novel and applicable chemotherapeutic
agents to cure viral diseases. Researches on the chemical structures and Antiviral Compounds (ACs) [8] of
uncommon metabolic products of aquatic life have
proven that marine organisms can provide excellent outlooks in the hunt for ADs [9]. Owing to the fact that
bivalves are in scarcity of a distinct adaptive immune
system, they must utilize their inborn immune system as a
A
http://journal.peerscientist.com Antiviral compounds from marine bivalves against SARS-CoV-2
Page 2 of 7
Volume 2 | Issue 2 | e1000015 Chee Kong Yap
protection against viral infections [10-11]. Besides the corporal obstacles of skin, shell, and epithelium, the
bivalves’ inborn immunity is also amplified by the
occurrence of numerous antimicrobial chemical agents
[12]. Biological diversity and ecological adaptations of bivalves hint at a potential source of novel ACs for future
AD discovery. In addition, ACs are a vital part of
bivalves’ defences against viruses with varied mechanisms of action against a wide array of viruses,
including human pathogens [13]. In this scenario, this
review aims at presenting potential antiviral compounds from marine bivalves, worth evaluating against SARS-
CoV-2.
Figure 02: 2D structure of mytilin compound from Mytilus galloprovincialis.
Tincu, J. A., and Taylor, S. W 2004 observed antimicrobial agents from marine bivalves can counteract
the invasions of pathogenic microbes effectively [14].
Olicard, C et.al 2005 [15] and Carriel‐Gomes et.al. 2006
[16] demonstrated antiviral activity in hemolymph from oysters, Crassostrea gigas and C. rhizophorae. Bilal
Muhammad Khan and Yang Liu, 2019 summarized that
secondary metabolites isolated from bivalves including mussel Mytilus galloprovincialis, mussel Crenomytilus
grayanus, clam Mercenaria mercenaria, clam Ruditapes
philippinarum, cockle Cerastoderma edule, clam Myaarenaria, oyster C. gigas, oyster C. virginica, and
oyster Ostrea edulis have been investigated as having AP
against many human related viruses [17]. Still, there are
about 100,000 species of mollusks that remain unverified for potential AP [13]. Kirsten Benkendorff 2009 reported
murexine, tyrindoleninone; 6-bromoisatin, 6,6’-
dibromoindirubin and 6,6’-dibromoindigo compounds as some of the important drug like compounds from
mollusks (figure 01) [18]. In recent review by Odeleye et
al. 2019, summarized main health benefits of molluscan
extracts include anti-cancer, antioxidant, and anti-infectious disease activities [19]. Chatterji et al. 2002
reported that the extracts from economically important
estuarine clam Meretrix casta, mussel P. viridis, mud clam Polymesoda erosa, oyster C. madrasensis, giant
oyster C. gryphoides, and black clam Villorita cyprinoide
were found to reduce the infection of influenza virus type-A and B to a great extent [20].
Figure 01: 2D structures of murexine, tyrindoleninone; 6-bromoisatin, 6,6’-dibromoindirubin and 6,6’-dibromoindigo compounds.
http://journal.peerscientist.com Antiviral compounds from marine bivalves against SARS-CoV-2
Page 3 of 7
Volume 2 | Issue 2 | e1000015 Chee Kong Yap
A comprehensive review by Dang et al. 2015
summarized most characterized extracts from bivalve
species with in vitro antiviral activity. Mytilin (figure 02) and Defensin (figure 03) from Mytilus galloprovincialis
showed direct inhibition of viral attachment and
transcription process. Defensins are cysteine rich 18-45 amino acid length peptides produced by innate immune
system and found highly active against a variety of
bacteria, fungi, enveloped and non-enveloped viruses
[13]. On the other hand, Tachyplesin I & II (figure 04) are another set of isopeptides isolated from hemocytes of
horseshoe crab (Tachypleus tridentatus and Limulus
polyphemus) were shown to directly inactivating several viruses including Vesicular stomatitis virus (VSV) and
Influenza (H1N1) virus [21].
Figure 03: 2D structure of Defensin compound from Mytilus galloprovinciali.s.
Figure 04: 2D structures of Tachyplesin I & II compounds from Tachypleus tridentatus and Limulus polyphemus.
Premalata Pati et.al, 2014 summarized unique
secondary metabolites with demonstrated anti-microbial activies. Dolastatin 10 & 15, Kahalaide F, Keenamide A
(figure 05), Turbostatin 1, Spisulosine-ES-285,
Ulapualide-A, and Ziconotide (figure 06) are some of the biologically active extracted, identified and isolated from
marine molluscs [22].
http://journal.peerscientist.com Antiviral compounds from marine bivalves against SARS-CoV-2
Page 4 of 7
Volume 2 | Issue 2 | e1000015 Chee Kong Yap
Maria Jose Abad Martinez et.al, 2008 reviewed
literature and summarized compounds from marine sources which are active against Human
Immunodeficiency Virus (HIV) are Avarol, avarone,
lamellarins, dragmacidin F, toxiusol; Herpes Simplex
Virus (HSV) are 4a-acetyldictyodial, pseudopterosins, helioporins, 8-hydroxymanzamine A, halovirs;
Cytomegalovirus (CMV) are Sulfolipids, plastoquinones,
pseudopterosin P and Influenza (H1N1) virus are Nostoflan and strongylin A; Human T- cell leukemia
virus , type 1 (HTLV-1) are Fistularin 3, 11-ketofistularin
3, kelletinin A; murine coronavirus is Halitunal; Hepatitis B (HBV) are neofolitispates, pentacyclic guanidine
alkaloids, Alpha-galactosylceramide and clavulone
against Vesicular Stomatitis Virus (VSV) (figure 07) [7].
Muhammed Zafar Iqbal and Khan 2016 reported
a novel DNAse like compound that can inhibit viral
propagation from the green-lipped mussel Perna viridis. They explored DNAse like bioactivity for natural non-
proteinacious compound(s) extracted from P. viridis.
These results indicated the prospect of a source of potential AD against DNA Group I viruses. Muhammed
Zafar Iqbal and Khan speculated that the marine mussels
have evolved some mechanisms against viral infections which need further studies [22].
Figure 05: 2D structures of Dolastatin 10 & 15, Kahalaide F and Keenamide A compounds.
http://journal.peerscientist.com Antiviral compounds from marine bivalves against SARS-CoV-2
Page 5 of 7
Volume 2 | Issue 2 | e1000015 Chee Kong Yap
Figure 06: 2D structures of Turbostatin 1, Spisulosine-ES-285, Ulapualide-A, and Ziconotide compounds.
http://journal.peerscientist.com Antiviral compounds from marine bivalves against SARS-CoV-2
Page 6 of 7
Volume 2 | Issue 2 | e1000015 Chee Kong Yap
II. CONCLUSION
In conclusion, all the above literature indicates that
various marine sources, especially marine bivalves holds
rich diversity of compounds from structural classes
including alkaloids, terpenoids, steroids, polysaccharides, and peptides etc., with potential antiviral potency which
can be used for further studies towards converting them
into antiviral drugs. Owing to the fact that bivalves are totally depended on their inborn immune system to
protect themselves against viral infections, they are bound
to develop a wide range of compounds which are hard to
find elsewhere. Taking these compounds as start point, potential target specific drug like compounds can be
Figure 07: 2D structures of Dolastatin 10 & 15, Kahalaide F, Keenamide A, Turbostatin 1, Spisulosine-ES-285, Ulapualide-A, and Ziconotide compounds.
http://journal.peerscientist.com Antiviral compounds from marine bivalves against SARS-CoV-2
Page 7 of 7
Volume 2 | Issue 2 | e1000015 Chee Kong Yap
designed to tackle viral infections, including present
SARS-CoV-2 infections.
REFERENCES
1. Zhu, Na, et al. “A novel coronavirus from patients with pneumonia in China, 2019.” New England Journal of Medicine(2020).
2. Worldometer. https://www.worldometers.info/coronavirus/ (Accessed on April 11, 2020).
3. Ruan, YiJun, et al. “Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection.” The Lancet9371 (2003): 1779-1785.
4. WHO MERS-CoV Research Group. “State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans.” PLoS currents5 (2013). doi: 10.1371/currents.
outbreaks.0bf719e352e7478f8ad85fa30127ddb8 5. Zhang, Z., Sheng, C., Ma, Z. and Li, D“The outbreak pattern of the
SARS cases in Asia.” Chinese Sci. Bull., 49(17) (2002):1819-1823. 6. Christian, D., Muth, Doreen, M., Victor, C., Hussain, Raheela, H.,
Malaki, M., Waleed, O., Olfert, L., Abdullah, A., Isabella, E., Ali, S., Jaffar, Al-T., Ali, A., Alimuddin, Z., Andrew, R., and Ziad, M. “An observational, laboratory-based study of outbreaks of middle east respiratory syndrome coronavirus in Jeddah and Riyadh,
Kingdom of Saudi Arabia.” Clin. Infect. Diseases. (2014). DOI: 10.1093/cid/ciu812.
7. Abad Martinez, M.J., Bedoya Del Olmo, L.M., and Bermejo Benito, P. “Natural marine antiviral products.” Stud. Nat. Prod. Chem., 35C (2008): 101-134.
8. Basha, Syed Hussain. “Corona virus drugs–a brief overview of past, present and future.” Journal of PeerScientist 2.2 (2020): e1000013.
9. Che, C.‐T. “Marine products as a source of antiviral drug leads.”
Drug Develop. Res., 23(3) (1991): 201-218. 10. Hooper, C., Day, R., Slocombe, R., Handlinger, J., and
Benkendorff, K. “Stress and immune responses in abalone: Limitations in current knowledge and investigative methods based on other models.” Fish Shellfish Immunol., 224 (2007): 363–379.
11. Tiscar, P., and Mosca, F. “Defense mechanisms in farmed marine molluscs.” Vet. Res. Comm., 281 (2004): 57–62.
12. Bachere, E., Mialhe, E., Noel, D., Boulo, V., Morvan, A., and Rodriguez, J. “Knowledge and research prospects in marine mollusc and crustacean immunology.” Aquaculture, 1321 (1995):
17–32. 13. Dang, V. T., Benkendorff, K., Green, T., and Speck, P. “Marine
snails and slugs: A great place to look for antiviral drugs.” J. Virol., 89 (2015): 8114–8118.
14. Tincu, J. A., and Taylor, S. W. Antimicrobial peptides from marine invertebrates. Antimicrobial Agents Chemotherapy, 4810 (2004): 3645-3654.
15. Olicard, C., Renault, T., Torhy, C., Benmansour, A., and
Bourgougnon, N. “Putative antiviral activity in hemolymph from adult Pacific oysters, Crassostrea gigas.” Antiviral Res., 662–3 (2005): 147-152.
16. Carriel‐Gomes, M. C., Kratz, J. M., Müller, V. D., Barardi, C. R.,
and Simões, C. M. “Evaluation of antiviral activity in hemolymph from oysters Crassostrea rhizophorae and Crassostrea gigas.” Aquat. Liv. Resour., 192 (2006):189–193.
17. Khan, B. M., and Liu, Y. “Marine mollusks: Food with benefits.” Compreh. Rev. Food Sci. Food Saf., 18 (2019):548-564.
18. Benkendorff, K. “Molluscan biological and chemical diversity: Secondary metabolites and medicinal resources produced by marine molluscs.” Biol. Rev., 85(4) (2010): 757–775.
19. Odeleye, T., White, W.L., and Lu, J. “Extraction techniques and potential health benefits of bioactive compounds from marine molluscs: A review.” Food Funct., 105 (2019): 2278-2289.
20. Chatterji, A., Ansari, Z.A., Ingole, B.S., Bichurina, M.A., Sovetova, M., and Boikov, Y.A. “Indian marine bivalves: Potential source of antiviral drugs.” Curr. Sci., 8210 (2002): 1279-1282.
21. Murakami, Tsukasa, et al. "Direct virus inactivation of tachyplesin I and its isopeptides from horseshoe crab hemocytes." Chemotherapy 37.5 (1991): 327-334.
22. Pati, P., Sahu, B.K., and Panigrahy, R.C. “Marine molluscs as a potential drug cabinet: An overview.” Indian J. Geo-Mar. Sci., 44(7) (2015): 961-970.
23. Muhammed Zafar Iqbal, A.N., and Khan, M.S. “A novel DNAse like compound that inhibits virus propagation from Asian green
mussel, Perna viridis Linn.” Indian J. Exp. Biol., 54 (2016): 816-821.
Submit your next manuscript to Journal of PeerScientist and
take full advantage of:
High visibility of your research across globe via PeerScientist network
Easy to submit online article submission system
Thorough peer review by experts in the field
Highly flexible publication fee policy
Immediate publication upon acceptance
Open access publication for unrestricted distribution
Submit your manuscript online at:
http://journal.peerscientist.com/